Page last updated: 2024-09-04

levofloxacin and daunorubicin

levofloxacin has been researched along with daunorubicin in 6 studies

Compound Research Comparison

Studies
(levofloxacin)
Trials
(levofloxacin)
Recent Studies (post-2010)
(levofloxacin)
Studies
(daunorubicin)
Trials
(daunorubicin)
Recent Studies (post-2010) (daunorubicin)
4,3465812,2098,2398861,310

Protein Interaction Comparison

ProteinTaxonomylevofloxacin (IC50)daunorubicin (IC50)
72 kDa type IV collagenaseHomo sapiens (human)1.9
Multidrug resistance-associated protein 1 Homo sapiens (human)8
Histone deacetylase 1Homo sapiens (human)0.047
Histone deacetylase 8Homo sapiens (human)0.22
Histone deacetylase 6Homo sapiens (human)0.02

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (16.67)18.2507
2000's2 (33.33)29.6817
2010's3 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gibbons, S; Kaatz, GW; Zloh, M1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Inui, KI; Ito, T; Tanaka, K; Yano, I1
Head, BM; Meyers, AF; Rubinstein, E1

Reviews

2 review(s) available for levofloxacin and daunorubicin

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Alternative pre-approved and novel therapies for the treatment of anthrax.
    BMC infectious diseases, 2016, Nov-03, Volume: 16, Issue:1

    Topics: Alpha-Globulins; Anthrax; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, Bacterial; Antitoxins; Bacillus anthracis; Bacterial Toxins; Daunorubicin; DNA Helicases; Doxorubicin; Drug Discovery; Fluoroquinolones; Humans; Interferon Inducers; Levofloxacin; Linezolid; Moxifloxacin; Ofloxacin; Polyketides; Serine Proteinase Inhibitors; Tilorone; Virulence

2016

Other Studies

4 other study(ies) available for levofloxacin and daunorubicin

ArticleYear
Inhibitors of multidrug resistance (MDR) have affinity for MDR substrates.
    Bioorganic & medicinal chemistry letters, 2004, Feb-23, Volume: 14, Issue:4

    Topics: Anti-Bacterial Agents; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Biological Transport; Cell Membrane; Drug Resistance, Microbial; Drug Resistance, Multiple; Ligands; Models, Molecular

2004
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1.
    The Journal of pharmacology and experimental therapeutics, 1997, Volume: 282, Issue:2

    Topics: Animals; Anti-Infective Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Daunorubicin; Epithelial Cells; Epithelium; Fluoroquinolones; Humans; Kidney; Levofloxacin; LLC-PK1 Cells; Ofloxacin; Quinolones; Swine

1997